Esperion Therapeutics Inc (NASDAQ:ESPR) Insider Trading Activity – Director Sold 15,329 shares of Stock

ME Staff
-
0

Insider Trading Activity For Esperion Therapeutics Inc (NASDAQ:ESPR)

Nicole Vitullo , Director of Esperion Therapeutics Inc (NASDAQ:ESPR) reportedly Sold 15,329 shares of the company’s stock at an average price of 44.73 for a total transaction amount of $685,666.17 SEC Form

Insider Trading History For Esperion Therapeutics Inc (NASDAQ:ESPR)

  • On 7/1/2013 Timothy M Mayleben, CEO, bought 5,000 with an average share price of $14.00 per share and the total transaction amounting to $70,000.00.
  • On 7/1/2013 Roger S Newton, Chairman, bought 42,346 with an average share price of $14.00 per share and the total transaction amounting to $592,844.00.
  • On 7/1/2013 Daniel Janney, Director, bought 235,714 with an average share price of $14.00 per share and the total transaction amounting to $3,299,996.00.
  • On 7/1/2013 Brian H Dovey, Major Shareholder, bought 285,714 with an average share price of $14.00 per share and the total transaction amounting to $3,999,996.00.
  • On 10/7/2014 Longitude Capital Partners, Ll, Major Shareholder, sold 11,927 with an average share price of $30.04 per share and the total transaction amounting to $358,287.08.
  • On 10/21/2014 Parters Vii L P Domain, Major Shareholder, bought 500,000 with an average share price of $20.00 per share and the total transaction amounting to $10,000,000.00.
  • On 11/18/2014 Patrick G Enright, Director, sold 487,130 with an average share price of $32.78 per share and the total transaction amounting to $15,968,121.40.

    • Analyst Ratings History For Esperion Therapeutics Inc (NASDAQ:ESPR)

    • On 8/21/2017 Jefferies Financial Group Reiterated Rating Buy with a price target of $85.00
    • On 3/8/2018 JMP Securities Boost Price Target of rating Outperform with a price target of $60.00 to $153.00
    • On 5/2/2018 Bank of America Reiterated Rating Buy to Underperform
    • On 5/3/2018 Deutsche Bank Lower Price Target of rating Buy to Buy with a price target of $100.00 to $75.00
    • On 5/4/2018 Credit Suisse Group Lower Price Target of rating Outperform to Outperform with a price target of $108.00 to $73.00
    • On 5/16/2018 UBS Group Set Price Target of rating Buy with a price target of $90.00 to $75.00
    • On 8/17/2018 Citigroup Upgraded rating Neutral to Buy with a price target of $57.00 to $75.00

    Recent Trading Activity for Esperion Therapeutics Inc (NASDAQ:ESPR)
    Shares of Esperion Therapeutics Inc closed the previous trading session at with 106550 shares trading hands.